Litcius/Paper detail

Identification of a PCSK9-LDLR disruptor peptide with in vivo function

Margaret E. Brousseau, Kevin B. Clairmont, Glen Spraggon, Alec N. Flyer, Andrei A. Golosov, Philipp Grosche, Jakal Amin, Jérôme André, Debra Burdick, Shari L. Caplan, Guanjing Chen, Raj Chopra, Lisa Ames, Diana Dubiel, Li Fan, Raphael Gattlen, Dawn Kelly-Sullivan, Alexander Koch, Ian Lewis, Jingzhou Li, Eugene Liu, Danuta Lubicka, Andreas L. Marzinzik, Katsumasa Nakajima, David O. Nettleton, Johannes Ottl, Meihui Pan, Tajesh Patel, Lauren M. Perry, Stephanie Pickett, Jennifer Poirier, Patrick Reid, Xavier Pellé, Mohindra Seepersaud, Vanitha Subramanian, Victoria Vera, Mei Xu, Lihua Yang, Qing Yang, Jinghua Yu, Guoming Zhu, Lauren G. Monovich

2021Cell chemical biology49 citationsDOI

Topics & Concepts

LDL receptorProprotein convertasePCSK9KexinIn vivoChemistryReceptorAllosteric regulationCholesterolPharmacologyBiochemistryCell biologyLipoproteinBiologyGeneticsLipoproteins and Cardiovascular HealthMonoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research
Identification of a PCSK9-LDLR disruptor peptide with in vivo function | Litcius